文献速递细胞病理与分子病理

米兰系统唾液腺细胞病理学对颌下腺病变的验证与FNA诊断准确性

Validation of the Milan System for Reporting Salivary Gland Cytopathology and the diagnostic accuracy of FNA cytology for submandibular gland lesions.
PubMed 文献 · Cancer Cytopathol · 2021-11-30

本研究基于荷兰病理登记库(PALGA)回顾性纳入2006至2017年间837例患者共975次颌下腺FNA标本,按米兰系统(MSRSGC)分类并计算各类别恶性风险。结果显示各类别恶性风险分别为:无诊断性14.4%、非肿瘤性4.4%、意义不明异型性37.0%、良性肿瘤3.9%、恶性潜能未定唾液腺肿瘤40.7%、可疑恶性76.2%、恶性91.3%;诊断恶性颌下腺肿瘤的敏感度71.6%、特异度98.4%。结论验证了MSRSGC用于颌下腺病变的可行性,恶性风险随解剖亚部位不同而变化。

要点

  • MSRSGC各类别恶性风险在颌下腺中与总体人群存在差异,需按亚部位解读。
  • 颌下腺FNA诊断恶性肿瘤敏感度71.6%、特异度98.4%。
  • MSRSGC推荐的管理策略适用于颌下腺病变。

核心结论

  • 本研究验证了MSRSGC分类系统可用于颌下腺病变的细胞病理学评估。
  • 颌下腺病变的恶性风险随唾液腺解剖亚部位不同而有所变化。

研究设计与样本

  • 基于荷兰病理登记库(PALGA)的回顾性队列研究。
  • 纳入2006年1月1日至2017年1月1日期间接受颌下腺切除且术前有FNA的患者。
  • 共纳入837例患者、975次颌下腺FNA标本,按MSRSGC回顾性分类并计算恶性风险及诊断准确性。

主要发现

  • 各MSRSGC类别恶性风险:无诊断性14.4%、非肿瘤性4.4%、意义不明异型性37.0%、良性肿瘤3.9%、恶性潜能未定唾液腺肿瘤40.7%、可疑恶性76.2%、恶性91.3%。
  • 诊断恶性颌下腺肿瘤的敏感度为71.6%,特异度为98.4%。

关键数值与推荐

  • MSRSGC各类别恶性风险:无诊断性14.4%、非肿瘤性4.4%、意义不明异型性37.0%、良性肿瘤3.9%、恶性潜能未定唾液腺肿瘤40.7%、可疑恶性76.2%、恶性91.3%。
  • 颌下腺FNA诊断恶性肿瘤的敏感度71.6%、特异度98.4%。

临床怎么用

  • 颌下腺FNA结果可按MSRSGC分类解读,并参考各类别恶性风险进行临床管理。
  • MSRSGC推荐的管理策略可应用于颌下腺病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Milan System for Salivary Gland Cytopathology (MSRSGC) is a categorical system for salivary gland fine-needle aspiration cytopathology (FNAC) developed to aid clinicians in the management of salivary gland lesions. This classification is widely studied and validated, especially in cohorts that consist of mostly parotid gland lesions. However, only sparse literature describes the use of this classification for submandibular gland lesions in particular. METHODS: All patients in the Netherlands that underwent a submandibular gland resection between January 1, 2006, and January 1, 2017, with a FNAC before resection were identified with the use of the Dutch Pathology Registry database (PALGA). All FNAC results were retrospectively classified according to the MSRSGC. The risk of malignancy was calculated for all the MSRSGC categories. The sensitivity and specificity of the MSRSGC classification were calculated for submandibular gland FNAC. RESULTS: A total of 837 patients who underwent 975 FNAC aspirates from the submandibular glands were included in the analysis. Risks of malignancy for each of the MSRSGC categories were 14.4% in nondiagnostic, 4.4% in nonneoplastic, 37.0% in atypia of unknown significance, 3.9% in benign neoplasms, 40.7% in salivary gland neoplasms of unknown malignant potential, 76.2% in suspected malignant, and 91.3% in malignant cytology results. The sensitivity for diagnosing malignant submandibular gland tumors was 71.6% and specificity was 98.4%. CONCLUSIONS: The results of the present study validate the use of this classification for submandibular gland lesions. Risks of malignancy vary according to the anatomical subsites of the salivary gland lesions. LAY SUMMARY: The risks of malignancy of the various Milan System for Salivary Gland Cytopathology (MSRSGC) categories vary according to the anatomical subsite of the salivary gland lesion. The proposed management techniques of the MSRSGC are valid for use with submandibular gland lesions.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Reerds STH, van Engen-van Grunsven ACH, van den Hoogen FJA, et al. Validation of the Milan System for Reporting Salivary Gland Cytopathology and the diagnostic accuracy of FNA cytology for submandibular gland lesions. Cancer Cytopathol. 2021. PMID: 34847276. doi:10.1002/cncy.22532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。